Renju Vechurettu Raj, MD
Hematology & Oncology · Milwaukee, WINPI 1083961528
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by GSK at 37.4% of the total. Reporting peaked in 2021 at $39,615 and has fallen 50.4% since, to $19,632 in 2025. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $367.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$36K
- Gilead$20K
- Bristol Myers Squibb$14K
- Jazz Pharmaceuticals Inc.$13K
- Amgen$6K
- AbbVie$2K
- plus $5K from 33 others
Across 57 payments — averaging $535.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$20K
- Iovance Biotherapeutics, Inc.$10K
- Astellas Pharma Europe BV$729
What the payments were for
- Consulting fees$26,79528%
- Speaking & faculty fees$49,72652%
- Travel & lodging$11,66112%
- Food & beverage$7,6538%
- Education$5151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $36,007 |
| Gilead | 30 | $20,288 |
| Bristol Myers Squibb | 26 | $14,398 |
| Jazz Pharmaceuticals Inc. | 16 | $13,001 |
| Amgen | 12 | $5,631 |
| AbbVie | 11 | $2,405 |
| Johnson & Johnson | 18 | $727 |
| Astellas Pharma US Inc | 10 | $489 |
| Novartis | 8 | $299 |
| Sanofi | 10 | $260 |
| Genentech USA, Inc. | 12 | $241 |
| Incyte Corporation | 7 | $235 |
| E.r. Squibb & Sons, L.L.C. | 6 | $200 |
| Merck | 6 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $161 |
| Iovance Biotherapeutics, Inc. | 3 | $158 |
| Daiichi Sankyo Inc. | 7 | $151 |
| Pfizer | 7 | $151 |
| Sanofi-aventis U.S. LLC | 2 | $147 |
| Gamida Cell Inc.(2 entities) | 2 | $132 |
| Legend Biotech USA Inc. | 3 | $122 |
| ADC Therapeutics America, Inc. | 4 | $116 |
| Seagen Inc. | 3 | $116 |
| Novo Nordisk | 1 | $112 |
| Bioverativ Therapeutics Inc. | 1 | $99 |
| Genmab U.S., Inc. | 3 | $98 |
| AstraZeneca | 4 | $79 |
| Syndax Pharmaceuticals, Inc. | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Regeneron | 1 | $38 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $18 |
| Dova Pharmaceuticals | 1 | $18 |
| Morphosys, US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,350 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 13 | $78,343 |
| EliquisApixaban | 21 | $12,346 |
| ValacyclovirValacyclovir Hcl | 25 | $1,138 |
| Hydrocortisone | 16 | $407 |
| Acyclovir | 22 | $236 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $72 |
| Doxycycline Hyclate | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncCresemba | $489 | $78,34313 claims |
| PfizerEliquis | $151 | $12,34621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.